TCR2 Therapeutics Inc expected to post a loss of 75  cents a share - Earnings Preview

TCR2 Therapeutics

08/03/2022 02:09

* TCR2 Therapeutics Inc  TCRR.OQ   TCRR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 9
(estimated). 
    * ​Refinitiv's mean analyst estimate for TCR2 Therapeutics
Inc is
for a loss of 75 cents per share. For the same quarter last
year, the company reported a loss of 55 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $22​, about 88.5% above​ its last closing price
of $2.52. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.69       -0.65      -0.69     Missed  -6.3
 Jun. 30 2021  -0.61       -0.59      -0.64     Missed  -8.8
 Mar. 31 2021  -0.53       -0.53      -0.58     Missed  -10.4​
 Dec. 31 2020  -0.52       -0.56      -0.55     Beat    2
 ​​Sep.        -0.54       -0.53      -0.56     Missed  -5.4
 30 2020                                                
 Jun. 30 2020  -0.67       -0.65      -0.67     Missed  -2.4​
 Mar. 31 2020  -0.61       -0.60      -0.65     Missed  -7.4
 Dec. 31 2019              -0.67      -0.54     Beat    19
 This summary was machine generated March 8 at 02:09 GMT.  All
figures in US dollars  unless otherwise stated